Efeito do COVID-19 sobre eventos tromboembólicos e controle deste com anticoagulantes / Effect of COVID-19 on thromboembolic events and its control with anticoagulant

Gustavo Mariano Rodrigues Santos, Daniella de Lourdes Baggio Rehfeld Ribeiro, Emanuela Carvalho Rodrigues, Giovanna Maiolli Signori, Kesley Silveira de Albuquerque, Letícia Prestini Tomelin, Luisa Bambirra Pereira, Maria Beatriz Siqueira de Araújo, Natália Ferrari, Tereza Dália de Freitas Barroso, Thaís Nacur Pimenta

Abstract


INTRODUÇÃO: A COVID-19, está associada à inflamação e a um estado pró-trombótico com um prognóstico ruim. O objetivo deste trabalho é avaliar o uso de anticoagulantes como profilaxia e/ou tratamento em eventos tromboembólicos em pacientes com COVID-19. METODOLOGIA:Trata-se de uma revisão sistemática, com busca realizada nas bases de dados clinicaltrials.gov e Pubmed, usando os descritores “anticoagulant” , “COVID-19”. Foram considerados artigos publicados em 2020 e 2021. RESULTADOS: Observou-se que pacientes com COVID-19 têm níveis elevados de dímero-D, altas taxas de tromboembolismo venoso e coagulação intravascular disseminada. Além disso, observou-se que o uso de dose maior de HBPM, como profilaxia tromboembólica, reduziu a incidência de complicações trombóticas. DISCUSSÃO: A heparina mostra-se eficaz na prevenção de fenômenos tromboembólicos durante a infecção pelo COVID19. Além disso, o aumento dos níveis de dímero D e inflamação sistêmica apresentam-se como fatores de mau prognóstico. Já à dose da anticoagulação, corroborou-se o uso de doses baixas na prevenção de eventos trombóticos, porém, divergiu-se quanto ao uso de doses intermediárias. CONCLUSÃO: Há um consenso de que a COVID-19 aumenta a probabilidade de eventos tromboembólicos, porém, há a necessidade de mais estudos sobre a utilização de terapia anticoagulante, e suas doses, em pacientes com COVID19.


Keywords


anticoagulante”, “COVID-19”, “tromboembolismo”.

References


Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., ... & Parikh, S. A. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. Journal of the American College of Cardiology, 2020;75(18):2352-2371.

Han, H., Yang, L., Liu, R., Liu, F., Wu, K., Li, J., … & Zhu, C. L. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med, 2020; 58(7): 1116-1120.

Madhavan, M. V., Bikdeli, B., Jimenez, D.,Chuich, T., Dreyfus, I., Driggin, E., … & Lip, G. Y. H. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2020;75(23):2950-2973.

Luo, H. C., You, C. Y., Lu, S. W., Fu, Y. Q. Characteristics of coagulation alteration in patients with COVID-19. Annals of Hematology, 2020; 100(1):45-52.

National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021.

Lillicrap, D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. Journal of Thrombosis and Haemostasis, 2020;18:786-787.

Marietta, M., Ageno, W., Artoni, A., Gresele, P., Marchetti, M., Marcucci, R., … & Tripodi, A. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2020; 18:(3):167-169.

Marietta, M., Ageno, W., Artoni, A. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Internal and Emergency Medicine, 2020;15(8):1375-1387.

Barnes, G. D., Burnett, A., Allen, A., Blumenstein, M., Clark, N. P., … & Minichiello, T. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Haemostasis, 2020;50(1):72-81.

Santos Cristina Mamédio da Costa, Pimenta Cibele Andrucioli de Mattos, Nobre Moacyr Roberto Cuce. A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Rev. Latino-Am. Enfermagem, 2007 Junho; 15( 3 ): 508-511.

Galvão Taís Freire, Pereira Mauricio Gomes. Revisões sistemáticas da literatura: passos para sua elaboração. Epidemiol. Serv. Saúde, 2014 Março; 23( 1 ): 183-184.

De Carvalho, A., Silva, V., Grandeet, A. J. Avaliação do risco de viés de ensaios clínicos randomizados pela ferramenta da colaboração Cochrane. Diagnóstico e Tratamento, 2013;18(1):38-44.

Al-Samkari H. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. The American Society of Hematology. 23 july 2020, v. 136, number 4, p. 489-500.

Ibañez C. et al. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? Journal of Thrombosis and Thrombolysis 15 july 2021, 51, p. 308-312.

Vanassche, T. et al. A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials 21, 1005, 9 december 2020.

Lemos ACB et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thrombosis Research, 196, 2020 359–366.

Meizlish ML et al. Intermediate-dose anticoagulation, aspirin, and in-hospitalmortality in COVID-19: A propensity score-matched analysis. Am J Hematol, 96, 2021, 471–479.

Gonzalez-Ochoa AJ. et al. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. Thromb Haemost. 2021.

Jonmarker S. et al. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care. 2020 Nov 23;24(1):653.

Stessel B. et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020 Oct;194:209-215.

Batschauer APB, Jovita HW. Hemostasia e COVID-19: fisiopatologia, exames laboratoriais e terapia anticoagulante. Rev bras anal clin. 2020; 52(2): 138-42.

Gomes AIM, Vidigal AS, Leite LDG, Alves GC, Souza TF, Santos NBD. Covid-19 e o seu efeito pró-trombótico: uso de tromboprofilaxia no tratamento. Hematol Transfus Cell Ther. 2020; 42: 523.

Soeiro AM, Leal TCAT, Pereira MP, Lima EG, Figueiredo ACBS, Petriz JLF, Precoma DB, Serrano Jr CV. Posicionamento sobre Uso de Antiplaquetários e Anticoagulantes nos Pacientes Infectados pelo Novo Coronavírus (COVID-19). Arq Bras Cardiol. 2020; 115(2): 292-301.

Qian Y, Xie H, Tian R, Yu K, Wang R. Efficacy of Low Molecular Weight Heparin in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Receiving Ventilatory Support. COPD. 2014; 11(2). 171-6.

Poloni JAT, Jahnke VS, Rotta LN. Insuficiência renal aguda em pacientes com COVID-19. Rev bras anal clin. 2020; 52(2): 160-7.

Lima T, Nunes L. Use of medicines for COVID19 treatment in patients with loss of kidney function: a narrative review. J Bras Nefrol. 2020; Available from: https://doi.org/10.1590/2175-8239-JBN-2020-0105.

Colling ME, Kanthi Y. COVID-19 associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020; 25(5): 471-8.

Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and rationale for anticoagulation. Clin Appl Thromb Hemost. 2020; 26: 1-7

Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, Zhang J. Association of elevated inflammatory markers and severe COVID-19. Medicine (Baltimore). 2020; 99(47): 1-12.

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sargentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95; 834-47.

Rodrigues RR, Correia T, Guimarães HP, Bignoto T, Camacho EC, Souza GM, Cordioli RL, Prado Junior PS, Campos NS, Guerra JC.. Recomendações sobre Manejo da Anticoagulação nos Pacientes com COVID-19. Associação Brasileira de Medicina de Emergência (ABRAMEDE). Disponível em: http://abramede.com.br/wp-content/uploads/2020/06/Recomendacoes-Manejo-Anticoagulacao-V01-090620.pdf

Pereira CS, Lima LM, Parente AAAI, Sant'Anna MFP. Opções de tratamento para COVID-19. Socied Bras Ped. 2020; 10(3): 1-4.

Nascimento JHP, Gomes BFO, Carmo Júnior PR, Petriz JLF, Rizk SI, Costa BSS, Lacerda MVG, Bacal F, Hajjar LA, Oliveira GMM. COVID-19 e estado de hipercoagulabilidade: uma nova perspectiva terapêutica. Arq Bras Cardiol. 2020; 114(5): 829-833

Rossi FH. Tromboembolismo venoso em pacientes COVID-19. J vasc bras. 2020; 19: 1-5.

Prudente ALA, Neto FCC, Silva, ITBQ, Alves MM, Marinho FCA, Martins MMC. Protocolo de tratamento do novo coronavírus. Secretaria de Estado da Saúde Pública do Rio Grande do Norte. 2020. Disponível em: https://portalcovid19.saude.rn.gov.br/wp-content/uploads/2020/05/Protocolo-Tratamento-SESAP-COVID19-022021-versão-final.pdf

Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, et al. Associação de dose de tratamento anticoagulante com sobrevida hospitalar em pacientes hospitalizados com COVID-19. J Am Coll Cardiol. 2020; 76 : 122–24.

Haque S, Jawed A, Akhter N, Dar SA, Kjan F, Mandal RK, Areeshi MY, Lohani M, Wahid M. Acetylsalicylic acid (Aspirin): a potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism. 2020; 24(18):9244-5.

Roberto GA, Pacheco LR, Gusmão MR, Gabriel SA. COVID-19 e eventos tromboembólicos. ULAKES. 2020; 1: 50-9.

Obi AT, Barnes GD, Wakefield TW, Brown SRVT, Eliason JL, Arndt E, Henke PK. Practical diagnosis and treatment of suspected venous thromboembolism during COVID- 19 Pandemic. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2020; 8(4):526-34.

Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127:1-4.

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6): 1421-4.

Longhitano Y, Racca F, Zanza C, Muncinelli M, Guagliano A, Peretti E et al. Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study. Biology. 2020; 9(10): 1-12.

Garcés EO, Victorino JA, Veronese FV. Anticoagulação em terapias contínuas de substituição renal. Rev Assoc Med Bras. 2007; 53(5): 451-5.

Mooney I, Thomas M, English W. Guia prático para o tratamento intensivo de pacientes com COVID-19. ATOTW. 2020: 1-15. Disponível em: https://resources.wfsahq.org/wp-content/uploads/426_ATOTW_PORTUGUES.pdf

Errichi BM, Cesarone MR, Belcaro G, Marinucci R, Ricci A, et al. Prevention of recurrent Deep venous thrombosis with sulodex- ide: the SanVal registry. Angiology. 2004; 55(3): 243-9.

Andreozzi GM, Bignamini AA, Davi G, Palareti G, Matuska J, et al. Sulodexide for the prevention of recurrent venous thromboembolism: The sulodexide in secondary prevention of recurrent deep venous thrombosis (SURVET) study: A multicenter, randomized, double-blind, placebo-controlled study. Circulation. 2015; 132 (20): 1891-7.

Munari ACF, Cantu SOF, Huet NEL, Alfaro MAB. Could Sudolexide be Helpful in COVID19?. Ann Cardiol Vasc Med. 2021: 4(1): 1040-4. Disponível em: https://meddocsonline.org/annals-of-cardiology-and-vascular-medicine/could-sulodexide-be-helpful-in-COVID-19.pdf.

Azimi A. TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19. Disponível em: https://www.researchgate.net/profile/Arsalan-Azimi/publication/341482078_TMPRSS2_inhibitors_Bromhexine_Aprotinin_Camostat_and_Nafamostat_as_potential_treatments_for_COVID-19/links/5ec3cad4458515626cb5133b/TMPRSS2-inhibitors-Bromhexine-Aprotinin-Camostat-and-Nafamostat-as-potential-treatments-for-COVID-19.pdf

Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: mechanistic insights into current COVID-19 therapies. 2020; 46 (2): 467-88.




DOI: https://doi.org/10.34117/bjdv7n7-074

Refbacks

  • There are currently no refbacks.